34 results on '"Hendriks, L."'
Search Results
2. SP-0527 New neoadjuvant/adjuvant strategies for resectable disease.
3. OC-0438 Proton-therapy and concurrent chemotherapy in stage III NSCLC: effects on hematological toxicity.
4. 127P Does radiomics have added value in predicting the development of brain metastases in patients with radically treated stage III non-small cell lung cancer (NSCLC)?
5. 74P Predicting the risk of immunotherapy-induced versus other-cause pneumonitis in stage IV non-small cell lung cancer (NSCLC) patients treated with immune checkpoint inhibitors.
6. OC-0607 Pattern of brain metastases after HA-PCI and SRCF in SCLC: pooled findings of NCT01780675 and PREMER.
7. 110O Plasma circulating tumor DNA analysis (ctDNA) for molecular alteration detection in advanced non-small cell lung cancer (NSCLC) patients (pts) with isolated central nervous system (CNS) metastases (mts).
8. 1408PPrognostic factors in non-small cell lung cancer (NSCLC) patients (pts) with brain metastases (BM) treated with immune checkpoint inhibitors (ICI).
9. 1365PDScreening for brain metastases (BM) in patients (pts) with stage III non-small cell lung cancer (NSCLC), magnetic resonance imaging (MRI) or dedicated contrast-enhanced computed tomography (dCE-CT)? A prospective observational study.
10. 66O EGFR MUTATED PATIENTS (PTS): DIFFERENT PATTERN AND OUTCOME OF METASTATIC BONE DISEASE (MBD) AND BRAIN METASTASIS (BM)?
11. PD-0097: Impact of new Dutch guideline on patient selection for WBRT in a large lung cancer cohort.
12. Towards a framework in interaction training for staff working with clients with intellectual disabilities and challenging behaviour.
13. Amyloid precursor protein gene mutation in early-onset Alzheimer's disease.
14. PO-1302 Impact of FEV1 and DLCO on survival and lung toxicities in NSCLC patients treated with radiotherapy.
15. Sexual risk assessment for people with intellectual disabilities
16. PO-1025: Prognostic factors for PFS and OS in radically treated patients with oligometastatic NSCLC.
17. PO-1053 cost-effectiveness of prophylactic cranial irradiation in stage III non-small cell lung cancer.
18. 186P Pooled efficacy and safety data of alectinib (A) vs. crizotinib (C) from the randomized phase III ALEX and J-ALEX trials.
19. 1509TiP The 1825-EORTC, ALKALINE: Activity of lorlatinib based on ALK resistance mutations on blood in ALK positive NSCLC patients previously treated with second generation ALK inhibitor.
20. 1392P Safety and efficacy of crizotinib in MET mutated (METmut) advanced non-small cell lung Cancer (aNSCLC): Results from the Drug Rediscovery Protocol (DRUP).
21. OC-0089 Radiomics models from chest CT scan to predict brain metastases in radically treated stage III NSCLC.
22. Combined asteroseismology, spectroscopy, and astrometry of the CoRoT B2V target HD 170580.
23. 1130P Real-world data of osimertinib (osi) for the treatment of metastatic epidermal growth factor receptor (EGFR+) non-small cell lung cancer (NSCLC) patients (pts), with a focus on age, body mass index (BMI) and trough levels.
24. 959P The association of GTV and brain metastasis development in patients with stage III NSCLC.
25. 27P Influence of single nucleotide polymorphisms (SNPs) in drug transporters ABCB1 and ABCG2 on intracerebral osimertinib efficacy in patients with non-small cell lung cancer.
26. 113P Proton-therapy and concurrent chemotherapy in stage III NSCLC: Effects on durvalumab eligibility and safety profile.
27. 48P Efficacy of osimertinib (osi) on (prevention of) bone metastases (mets) and skeletal related events (SREs) in patients (pts) with epidermal growth factor receptor mutated (EGFRm+) non-small cell lung cancer (NSCLC).
28. LBA79 Dutch oncology COVID-19 Consortium (DOCC): Outcome of COVID-19 in patients with cancer in a nationwide cohort study.
29. 1417TiP Immunotherapy, chemotherapy and stereotactic radiotherapy to metastases, followed by definitive surgery or radiotherapy to the primary tumour, in patients with synchronous oligo-metastatic NSCLC: The ETOP CHESS trial.
30. Nonviral transfection of distinct types of human dendritic cells: high-efficiency gene transfer by electroporation into hematopoietic progenitor- but not monocyte-derived dendritic cells.
31. PO-1813: Plasma biomarkers of immunogenic cell death during and after SBRT and concurrent chemo-RT for NSCLC.
32. 23P Immunosenescence (iSenescence) correlates with progression (PD) to PD-(L)1 inhibitors (IO) and not to platinum-chemotherapy (PCT) in advanced non-small cell lung cancer (aNSCLC) patients (pts).
33. PV-0208 Immune-related pneumonitis in NSCLC patients treated with ICI: impact of previous thoracic RT.
34. 1407PDerived neutrophil-to lymphocyte ratio (dNLR) change between baseline and cycle 2 is correlated with benefit during immune checkpoint inhibitors (ICI) in advanced non-small cell lung cancer (NSCLC) patients.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.